(Q38755912)

6 September 2017

Selected cytokine pathways in rheumatoid arthritis (English)

1 reference

6 September 2017

0 references

Mélissa Noack

1

1 reference

PubMed ID

28213794

6 September 2017

Pierre Miossec

series ordinal

2

1 reference

6 September 2017

17 February 2017

1 reference

Seminars in Immunopathology

6 September 2017

1 reference

6 September 2017

39

1 reference

6 September 2017

4

1 reference

6 September 2017

365-383

1 reference

https://scigraph.springernature.com/pub.10.1007/s00281-017-0619-z

6 September 2017

0 references

cites work

Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Signalling pathways of the TNF superfamily: a double-edged sword

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α: Receptors, functions, and roles in diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Interleukin 6 is required for the development of collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Efficacy and safety of the human anti-IL-1β monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Tocilizumab: is there life beyond anti-TNF blockade?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Cytokine imbalance in the pathogenesis of rheumatoid arthritis: the role of interleukin-1 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Immunogenicity and autoimmunity during anti-TNF therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Interleukin 17 contributes to the chronicity of inflammatory diseases such as rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

IL-17 in Chronic Inflammation: From Discovery to Targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

T-helper-1-cell cytokines drive cancer into senescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Evidence that cytokines play a role in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Regulation of tumour necrosis factor signalling: live or let die

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

The role of IL-1 in the pathogenesis of heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

SOCS-1 mediates ubiquitylation and degradation of GM-CSF receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

TNFα in the regulation of Treg and Th17 cells in rheumatoid arthritis and other autoimmune inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Impact of biologic therapy on functional status in patients with rheumatoid arthritis--a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Granulocyte-macrophage colony stimulating factor exacerbates collagen induced arthritis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

The role of IL-1β in the early tumor cell-induced angiogenic response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Identification of a key pathway required for the sterile inflammatory response triggered by dying cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Stromal-derived IL-6 alters the balance of myeloerythroid progenitors during Toxoplasma gondii infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

The problem of choice: current biologic agents and future prospects in RA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Differential release of chromatin-bound IL-1alpha discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Granulocyte-macrophage colony-stimulating factor is a key mediator in inflammatory and arthritic pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Granulocyte-macrophage colony-stimulating factor is a key mediator in experimental osteoarthritis pain and disease development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Granulocyte/macrophage colony-stimulating factor causes a paradoxical increase in the BH3-only pro-apoptotic protein Bim in human neutrophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Human recombinant interleukin 1 stimulates collagenase and prostaglandin E2 production by human synovial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Interleukin-1 in the pathogenesis and treatment of inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Human leukocytic pyrogen: purification and development of a radioimmunoassay

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

TNF Receptor 2 and Disease: Autoimmunity and Regenerative Medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Translating molecular insights in autoimmunity into effective therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Role of cytokines in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

The disease formerly known as rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Functions of granulocyte-macrophage colony-stimulating factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

GM-CSF- and M-CSF-dependent macrophage phenotypes display differential dependence on type I interferon signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Polymorphism at position -308 of the tumour necrosis factor alpha gene and rheumatoid arthritis pharmacogenetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

IL-1 pathways in inflammation and human diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Recent advances in the IL-17 cytokine family

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Structure and signalling in the IL-17 receptor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

The interleukin-1 family: back to the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Direct retrovirus-mediated gene transfer to the synovium of the rabbit knee: implications for arthritis gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Colony-stimulating factors in inflammation and autoimmunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

The structure of the GM-CSF receptor complex reveals a distinct mode of cytokine receptor activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

TNF provokes cardiomyocyte apoptosis and cardiac remodeling through activation of multiple cell death pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Signalling by the βc family of cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Blockade of TNF-α rapidly inhibits pain responses in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide D

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

IL-6 controls the innate immune response against Listeria monocytogenes via classical IL-6 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

IL-17 and tumour necrosis factor α combination induces a HIF-1α-dependent invasive phenotype in synoviocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

IL-6 as a keystone cytokine in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

The activity of JAK-STAT pathways in rheumatoid arthritis: constitutive activation of STAT3 correlates with interleukin 6 levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Functional specialization of interleukin-17 family members

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

The role of IL-1 and IL-1Ra in joint inflammation and cartilage degradation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Loss of CD4+ T cell IL-6R expression during inflammation underlines a role for IL-6 trans signaling in the local maintenance of Th17 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Directing transition from innate to acquired immunity: defining a role for IL-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Constitutive production of interleukin-6 and immunologic features in cardiac myxomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

TNF biology, pathogenic mechanisms and emerging therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Predictors for remission in rheumatoid arthritis patients: A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Circulating Ly-6C+ myeloid precursors migrate to the CNS and play a pathogenic role during autoimmune demyelinating disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Secukinumab for rheumatology: development and its potential place in therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Interleukin-17 family members and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Impaired immune and acute-phase responses in interleukin-6-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Acute CD4+ T lymphocyte-dependent interleukin-1-driven arthritis selectively requires interleukin-2 and interleukin-4, joint macrophages, granulocyte-macrophage colony-stimulating factor, interleukin-6, and leukemia inhibitory factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Spotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to date

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Tumor necrosis factor α induces sustained signaling and a prolonged and unremitting inflammatory response in rheumatoid arthritis synovial fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Infections in patients with rheumatoid arthritis treated with biologic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Act1, a U-box E3 ubiquitin ligase for IL-17 signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

The TNF and TNF receptor superfamilies: integrating mammalian biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Opposing Functions of Classic and Novel IL-1 Family Members in Gut Health and Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Overexpression of IL-17 in the knee joint of collagen type II immunized mice promotes collagen arthritis and aggravates joint destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Requirement of IL-17 receptor signaling in radiation-resistant cells in the joint for full progression of destructive synovitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Intracellular Signaling Pathways in Rheumatoid Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Rilonacept in the treatment of chronic inflammatory disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Cytokines in rheumatoid arthritis - shaping the immunological landscape

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Cytokines in the pathogenesis of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Targeting interleukin-6 in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Anakinra for rheumatoid arthritis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

The colony-stimulating factors and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

21 January 2018

Hematopoietic cytokines

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Illuminating the black box of TNF action in tuberculous granulomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Anti-interleukin 1alpha autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Interleukin-17 in rheumatoid arthritis: if T cells were to contribute to inflammation and destruction through synergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Targeting IL-17 and TH17 cells in chronic inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Interleukin-17 and type 17 helper T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

IL-1beta processing in host defense: beyond the inflammasomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

IL-6 is required for airway mucus production induced by inhaled fungal allergens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Interaction among activated lymphocytes and mesenchymal cells through podoplanin is critical for a high IL-17 secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

The STIR-domain superfamily in signal transduction, development and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

The JAK-STAT pathway: impact on human disease and therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Interleukin 6 plays a key role in the development of antigen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

A study to evaluate the safety, tolerability, and efficacy of brodalumab in subjects with rheumatoid arthritis and an inadequate response to methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Long-term remission of neutropenia in Felty's syndrome after a short GM-CSF treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

GM-CSF neutralisation suppresses inflammation and protects cartilage in acute streptococcal cell wall arthritis of mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

TNF and its receptors in the CNS: The essential, the desirable and the deleterious effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

IL-6 trans-signaling: the heat is on.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Interleukin-1 function and role in rheumatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

How cytokine networks fuel inflammation: Toward a cytokine-based disease taxonomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Remission in rheumatoid arthritis: wishful thinking or clinical reality?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Pivotal roles of GM-CSF in autoimmunity and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

GM-CSF but not IL-17 is critical for the development of severe interstitial lung disease in SKG mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

21 January 2018

Rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Familial autoinflammatory diseases: genetics, pathogenesis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Hematopoietic colony-stimulating factors: new players in tumor-nerve interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Anti-inflammatory mechanism of tocilizumab, a humanized anti-IL-6R antibody: effect on the expression of chemokine and adhesion molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

IL-6 and IL-1 synergistically enhanced the production of MMPs from synovial cells by up-regulating IL-6 production and IL-1 receptor I expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

The effect of gene polymorphisms on patient responses to rheumatoid arthritis therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Anti cytokine therapy in chronic inflammatory arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Role of interleukin 17 in arthritis chronicity through survival of synoviocytes via regulation of synoviolin expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Role of IL-17 in the Th1 systemic defects in rheumatoid arthritis through selective IL-12Rbeta2 inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Cutting edge: interleukin 17 signals through a heteromeric receptor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorates joint swelling in established monkey collagen-induced arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Interindividual and intra-articular variation of proinflammatory cytokines in patients with rheumatoid arthritis: potential implications for treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

A low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal gram-negative infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

GM-CSF as a therapeutic target in inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Complementary action of granulocyte macrophage colony-stimulating factor and interleukin-17A induces interleukin-23, receptor activator of nuclear factor-κB ligand, and matrix metalloproteinases and drives bone and cartilage pathology in experimenta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Tumour necrosis factor antagonists: structure, function, and tuberculosis risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, d

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Targeting GM-CSF in inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Cytokines in chronic inflammatory arthritis. II. Granulocyte-macrophage colony-stimulating factor in rheumatoid synovial effusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Animal models of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

The response to anti-TNF-α treatment: gene regulation at the bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Interleukin-17, a regulator of angiogenic factor release by synovial fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Trans-Signaling Is a Dominant Mechanism for the Pathogenic Actions of Interleukin-6 in the Brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Combined blockade of granulocyte-macrophage colony stimulating factor and interleukin 17 pathways potently suppresses chronic destructive arthritis in a tumour necrosis factor -independent mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-017-0619-Z

Evidence for GM-CSF receptor expression in synovial tissue. An analysis by semi-quantitative polymerase chain reaction on rheumatoid arthritis and osteoarthritis synovial biopsies

21 January 2018

1 reference

12 December 2020

The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model

1 reference

12 December 2020

Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis

1 reference

12 December 2020

Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130

1 reference

12 December 2020

Signaling conformations of the tall cytokine receptor gp130 when in complex with IL-6 and IL-6 receptor

1 reference

12 December 2020

Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha

1 reference

12 December 2020

Effects of Interleukin-17A on Osteogenic Differentiation of Isolated Human Mesenchymal Stem Cells

1 reference

12 December 2020

Hematopoietic colony–stimulating factors mediate tumor-nerve interactions and bone cancer pain

1 reference

12 December 2020

Stimulus-dependent requirement for granulocyte-macrophage colony-stimulating factor in inflammation

1 reference

12 December 2020

Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein

1 reference

12 December 2020

Classical and Paradoxical Effects of TNF-α on Bone Homeostasis

1 reference

12 December 2020

Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis

1 reference

12 December 2020

Tocilizumab in the treatment of rheumatoid arthritis and beyond

1 reference

12 December 2020

Altered susceptibility to collagen-induced arthritis in transgenic mice with aberrant expression of interleukin-1 receptor antagonist

1 reference

12 December 2020

IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation.

1 reference

12 December 2020

Expression of GM-CSF receptor in rheumatoid arthritis

1 reference

12 December 2020

Increased production of intracellular interleukin-1 receptor antagonist type I in the synovium of mice with collagen-induced arthritis: a possible role in the resolution of arthritis

1 reference

12 December 2020

Correction of granulocytopenia in Felty's syndrome by granulocyte-macrophage colony-stimulating factor. Simultaneous induction of interleukin-6 release and flare-up of the arthritis

1 reference

12 December 2020

Profile of cerebrospinal fluid and serum cytokines in patients with relapsing-remitting multiple sclerosis: a correlation with clinical activity

1 reference

12 December 2020

IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells

1 reference

12 December 2020

High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism

1 reference

12 December 2020

Angiogenesis in rheumatoid arthritis

1 reference

12 December 2020

The IL-1 family: regulators of immunity

1 reference

12 December 2020

Comparison of the in vivo inflammatory activities after intra-articular injection of natural and recombinant IL-1 alpha and IL-1 beta in the rabbit

1 reference

12 December 2020

Plasma GM-CSF concentrations in rheumatoid arthritis, systemic lupus erythematosus and spondyloarthropathy

1 reference

12 December 2020

Arthritis induced by interleukin-1 is dependent on the site and frequency of intraarticular injection

1 reference

12 December 2020

Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines.

1 reference

12 December 2020

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease

1 reference

12 December 2020

Flare-up of rheumatoid arthritis during GM-CSF treatment after chemotherapy

1 reference

12 December 2020

Protection from collagen-induced arthritis in granulocyte-macrophage colony-stimulating factor-deficient mice

1 reference

12 December 2020

Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease

1 reference

12 December 2020

Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice

1 reference

12 December 2020

Dependence of interleukin-1-induced arthritis on granulocyte-macrophage colony-stimulating factor

1 reference

12 December 2020

Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice

1 reference

12 December 2020

Interleukin-1 receptor antagonist inhibits proteoglycan breakdown in antigen induced but not polycation induced arthritis in the rabbit

1 reference

12 December 2020

IL-17 is a potent synergistic factor with GM-CSF in mice in stimulating myelopoiesis, dendritic cell expansion, proliferation, and functional enhancement

1 reference

12 December 2020

A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate

1 reference

12 December 2020

High levels of neutralizing autoantibodies against IL-1 alpha are associated with a better prognosis in chronic polyarthritis: a follow-up study

1 reference

12 December 2020

Cytokine regulation of colony-stimulating factor production in cultured human synovial fibroblasts: I. Induction of GM-CSF and G-CSF production by interleukin-1 and tumor necrosis factor

1 reference

12 December 2020

Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial

1 reference

12 December 2020

1 reference

12 December 2020

Interleukin-6 (IL-6) induces the proliferation of synovial fibroblastic cells in the presence of soluble IL-6 receptor

1 reference

12 December 2020

The Src-like adaptor protein regulates GM-CSFR signaling and monocytic dendritic cell maturation

1 reference

12 December 2020

Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses

1 reference

12 December 2020

Role of interleukin-1, tumor necrosis factor alpha, and interleukin-6 in cartilage proteoglycan metabolism and destruction. Effect of in situ blocking in murine antigen- and zymosan-induced arthritis

1 reference

12 December 2020

Enhancing effect of IL-1, IL-17, and TNF-alpha on macrophage inflammatory protein-3alpha production in rheumatoid arthritis: regulation by soluble receptors and Th2 cytokines

1 reference

12 December 2020

Targeting interleukin-1 in the treatment of rheumatoid arthritis

1 reference

12 December 2020

Negative association between autoantibodies against IL-17, IL-17/anti-IL-17 antibody immune complexes and destruction in rheumatoid arthritis

1 reference

12 December 2020

Granulocyte-macrophage colony-stimulating factor (CSF) and macrophage CSF-dependent macrophage phenotypes display differences in cytokine profiles and transcription factor activities: implications for CSF blockade in inflammation

1 reference

12 December 2020

Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist.

1 reference

12 December 2020

Interleukin-6 and the granulocyte colony-stimulating factor receptor are major independent regulators of granulopoiesis in vivo but are not required for lineage commitment or terminal differentiation.

1 reference

12 December 2020

A cell-based bioassay for circulating bioactive IL-17: application to destruction in rheumatoid arthritis

1 reference

12 December 2020

Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis

1 reference

12 December 2020

Serum and synovial fluid levels of interleukin-17 in correlation with disease activity in patients with RA

1 reference

12 December 2020

Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis

1 reference

12 December 2020

Arthritis induced by continuous infusion of hr-interleukin-1 alpha into the rabbit knee-joint.

1 reference

12 December 2020

Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium

1 reference

12 December 2020

Major role for interleukin 1 but not for tumor necrosis factor in early cartilage damage in immune complex arthritis in mice

1 reference

12 December 2020

Measurement of colony-stimulating factors in synovial fluid: potential clinical value

1 reference

12 December 2020

Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis

1 reference

12 December 2020

Constitutive intra-articular expression of human IL-1 beta following gene transfer to rabbit synovium produces all major pathologies of human rheumatoid arthritis

1 reference

12 December 2020

GM-CSF production by autoreactive T cells is required for the activation of microglial cells and the onset of experimental autoimmune encephalomyelitis

1 reference

12 December 2020

Human articular cartilage and chondrocytes produce hemopoietic colony-stimulating factors in culture in response to IL-1

1 reference

12 December 2020

IL-17RA and IL-17RC receptors are essential for IL-17A-induced ELR+ CXC chemokine expression in synoviocytes and are overexpressed in rheumatoid blood

1 reference

12 December 2020

Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis

1 reference

12 December 2020

10.1007/S00281-017-0619-Z

Identifiers

DOI

1 reference

PubMed ID

28213794

Dimensions Publication ID

6 September 2017

0 references

1 reference

PubMed ID

28213794